Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03399604 · ClinicalTrials.gov registry record · Phase 3
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
A Phase 3 study, sponsored by Liquidia Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT03399604: Completed Phase 3 study, sponsored by Liquidia Technologies.
NCT03399604 is a Phase 3 study that has completed, run by Liquidia Technologies. The registered enrollment target is 121 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03399604, a Phase 3 study, has completed, sponsored by Liquidia Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
Primary Outcome
There were two treatment arms analyzed for events in the study. All subjects that participated in the PK study were part of the transition group and not analyzed separately for adverse events. Treatment-Emergent Adverse Events and Serious Adverse Events will be grouped by MedDRA System Organ Class, dose level, time on drug, and relationship to dose titration
Interventions
- DRUG LIQ861 Inhaled Treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2019-11-25 |
| Phase | Phase 3 |
What the finished NCT03399604 record still lists
NCT03399604 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which LIQ861 Inhaled Treprostinil is the first listed.
NCT03399604 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03399604 about?
NCT03399604 is a clinical study titled "Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil". The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
What is the current status of trial NCT03399604?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2018-01-02. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT03399604?
The interventions under investigation include: LIQ861 Inhaled Treprostinil (DRUG).
Who is sponsoring clinical trial NCT03399604?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03399604's enrollment target sits among peer trials
121 1619th of 2000 higher than 382 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI